Articles tagged with Prostate Cancer
A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) offers a higher cure rate than traditional approaches, with a 98.6% cure rate for prostate cancer patients. The treatment involves high-dose radiation beams delivered in just five treatments, resulting in fewer side effects and quicker recovery times.
A new cancer treatment approach uses microparticles and mesenchymal stem cells to deliver chemotherapy directly to tumor cells, reducing systemic toxicity. The method successfully kills tumor cells via a strong bystander effect, offering hope for targeted treatment of prostate cancer and potentially other diseases.
Researchers at the University of Missouri have discovered a compound that not only lowers cholesterol but also kills prostate cancer cells. The study found that the compound, initially developed as a cholesterol-fighting molecule, reduced prostate cancer cell growth and caused cancer cell death in human and mouse models.
A study published in the Journal of Urology found that up to 30% of men on active surveillance for low-risk prostate cancer may have metastases. Risk factors include Gleason score 7 and presence of Gleason pattern 4 on diagnostic biopsy.
Researchers found that common treatments for prostate cancer can suppress the immune system, preventing immunotherapies from working effectively. The study suggests careful regulation of treatment timing and dosage to maximize anti-tumor effects and prevent relapse.
A clinical trial confirms that a shortened radiotherapy schedule is as effective as conventional radiotherapy in treating low-risk prostate cancer patients. Patients treated with the shorter regimen experienced more mild side effects, but no difference in severe late side effects.
A national study found that a shorter, intensive radiation therapy schedule of about 5.5 weeks was comparable to the standard 8-week regimen in terms of controlling cancer, while also reducing treatment duration and costs. The researchers reported slightly more mild side effects in patients receiving the shorter schedule.
A new genetic urine test has been developed to predict high-grade prostate cancer, identifying 92 percent of men with elevated PSA levels who had high-grade cancers. The test could spare hundreds of thousands of men from unnecessary biopsies and reduce the risks associated with the procedure.
Researchers have found that suppressing the nuclear receptor protein ROR-γ with small-molecule compounds can reduce androgen receptor levels in castration-resistant prostate cancer, stopping tumor growth. This novel approach targets the root cause of the problem - the overexpression of the AR gene and its protein.
The study suggests that PSA screening should be extended and higher biopsy thresholds used to preserve benefits while controlling harm and costs, potentially making it a more cost-effective strategy.
Researchers have identified 11 molecules capable of binding to the PSMA biomarker, making them potential treatments for prostate cancer. These ligands are suitable for synthesizing and have good pharmacokinetic parameters, increasing their effectiveness in clinical trials.
Researchers at the University of Georgia have created a new therapeutic for prostate cancer that has shown great efficacy in mouse models. The treatment, which involves packaging and administering a small molecule called IPA-3, significantly slows the progression of cancer and forces cancerous cells to undergo apoptosis.
A new study found that active surveillance for low-risk prostate cancer significantly improves urinary function, reduces incontinence, and enhances sexual satisfaction. Men on active surveillance reported a similar quality of life to those without cancer, highlighting its potential as an alternative to curative treatment.
Researchers have identified new prostate cancer markers in urine that show high specificity and sensitivity. A combination of these biomarkers could lead to a more accurate and reliable test for early diagnosis.
Researchers have found a correlation between hypogonadism and high Gleason scores in prostate cancer patients. This association could help predict patient outcomes before surgery, allowing for more targeted treatment strategies.
Researchers at the University of Missouri found that surgery can greatly increase a man's chance of survival when traditional radiation therapy has failed. A complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.
A CWRU researcher is using plant viruses to detect and treat aggressive prostate and breast cancers. The lab will customize tobacco mosaic virus to target biomarkers of prostate cancer and deliver chemotherapy deep into breast tumor tissue.
Research at Duke University Medical Center found that prostate cancer patients with lymph-only metastasis have the longest overall survival, while those with liver involvement fare worst. The study analyzed outcomes of 8,736 men with metastatic prostate cancer and provides valuable information on prognosis and treatment approaches.
Researchers at Karolinska Institutet and University of Oulu identified mechanisms explaining genetic variants' influence on prostate cancer risk. The study reveals widespread deregulation of androgen receptor function, a key player in prostate cancer.
Researchers have found a possible association between radiotherapy for prostate cancer and an increased risk of developing secondary cancers of the bladder, colorectal tract, and rectum. However, the absolute rates of these secondary cancers remain low compared to other treatment complications.
A new study by Northwestern University research found that low levels of vitamin D are associated with aggressive prostate cancer in men. Men with dark skin or limited sun exposure should get their vitamin D levels checked and supplement if necessary to reduce the risk of aggressive prostate cancer.
A new study from The Ottawa Hospital and the University of Ottawa shows that men with slow-growing prostate tumors are increasingly adopting active surveillance, a monitoring approach that avoids unnecessary treatment. After five years of follow-up, about 59% of patients under active surveillance were still managed that way.
A new clinical trial has begun at Oxford and Sheffield to test a potential vaccine for prostate cancer. The vaccine aims to stimulate the immune system's attack on cancer cells by recognizing a specific protein found on their surface. If successful, future studies will assess its effectiveness in preventing disease progression.
A study by the University of Texas M.D. Anderson Cancer Center reveals that adult stem cells in the prostate basal cell layer express genes similar to those found in deadly prostate cancer, offering a potential new line of treatment for highly aggressive and therapy-resistant forms.
Researchers at UT Southwestern Medical Center found that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85% accuracy. This technology aims to improve surgical decision-making and reduce the amount of healthy tissue removed during prostate cancer surgery.
Florida State University researchers are working on a new approach to deciphering genetic data that may lead to more targeted prostate cancer treatments. They identified altered signal pathways in prostate cancer, which could help pinpoint genetic changes that matter in cancer development and progression.
A new device can detect prostate cancer in urine samples using a gas chromatography sensor system, allowing for earlier diagnosis and potentially reducing the need for invasive procedures. The technology has shown promising results in a pilot study involving 155 men.
A study published in Circulation found that prostate cancer survivors are at higher risk of developing cardiovascular disease due to hormone therapy. The Vanderbilt Cardio-oncology program is working to modulate these risks through collaborative care and personalized interventions.
Declines in PSA testing varied by physician type, with primary care physicians showing a larger decrease than urologists. The study suggests that perceptions of PSA screening benefits and conflicting guidelines may contribute to the differences.
A new review suggests that targeted antibiotic therapy before prostate biopsy may lower sepsis rates. The study found 27 men need to receive antibiotics to prevent one infection, paving the way for safer procedures.
A new class of drug, YELIVA™ (ABC294640), has shown promise in slowing the growth of castration-resistant prostate cancer cells by inhibiting the sphingolipid pathway. The study found that treatment with YELIVA™ increased dihydroceramide levels and reduced expression of key oncogenes.
A recent study shows that a PET/CT scan using F-18-DCFBC is significantly more effective in detecting metastatic prostate cancer than other detection methods. The radiotracer targets prostate-specific membrane antigen, which is expressed in the majority of prostate cancers and associated with metastatic spread.
Researchers discovered a new biomarker, pro-NPY, which correlates with increased risk of prostate cancer death. The study suggests that high pro-NPY levels can predict prostate cancer-related death among diagnosed patients who haven't received surgical treatment.
A study found that 15.7% of individuals 65 or older received nonrecommended screenings for prostate and breast cancers due to limited life expectancy, costing the US healthcare system $1.2 billion annually. States with high rates of nonrecommended screening showed similar patterns in both prostate and breast cancer screenings.
A new study reveals that docetaxel retains effectiveness in patients with castration-resistant metastatic prostate cancer (mCRPC) treated with abiraterone. Following abiraterone, 40% of patients experienced a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this drug sequencing.
A recent study published in The Journal of Urology found that reduced prostate needle biopsies are associated with a higher risk of being diagnosed with high-risk disease. This could lead to delayed diagnosis and potentially avoidable cancer deaths. The study's findings highlight the need for balanced screening approaches and more effe...
A new study led by Sheffield Hallam University is exploring the potential of exercise as a treatment for prostate cancer. The PANTERA study involves 50 men with non-spreading cancer, who will either undergo supervised exercise sessions or receive information on exercise benefits but no sessions.*
A new study found that African American men with low-grade prostate cancer produce less PSA and have significantly lower PSA density than Caucasian men. This could lead to inaccurate surveillance criteria and affect treatment decisions for African American patients.
Researchers have found that screening male kidney transplant candidates for prostate cancer does not prolong their survival and may even delay receiving a transplant. Elevated PSA levels detected through screening were associated with a reduced likelihood of receiving a transplant regardless of the patient's age or PSA level.
Researchers at MD Anderson Cancer Center identified myeloid-derived suppressor cells (MDSCs) as a key player in advanced prostate cancer progression. Depletion of MDSCs and blocking specific signaling pathways showed promise in suppressing tumor growth, paving the way for potential therapeutic opportunities.
Researchers discovered an unexpected link between two common prostate cancer treatments, radiation and androgen ablation. This connection allows doctors to better determine which treatment will benefit individual patients, potentially leading to improved prostate cancer treatments.
A meta-analysis of 19 studies involving over 118,000 patients found that surgery resulted in lower mortality rates compared to radiation treatment. Patients treated with surgery were twice as likely to survive prostate cancer than those treated with radiation.
Researchers at Houston Methodist Hospital developed a suicide gene therapy that combines radiation treatment with a genetically modified virus to target and destroy cancer cells. The treatment shows high five-year overall survival rates of 97% and 94%, improving upon historical studies by 5-20%.
A new study from The Ottawa Hospital and the University of Ottawa found that repeating an abnormal PSA test reduces unnecessary biopsies by 55 percent. Men with conflicting test results who had a second normal test were diagnosed with cancer within a year, suggesting the importance of repeat testing.
A recent study found that PET/CT and whole-body MRI detect extraskeletal disease, changing cancer management. Combined administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan showed higher sensitivity and accuracy than alternative methods.
A Stanford University study has found that men treated with androgen deprivation therapy for prostate cancer are nearly twice as likely to be diagnosed with Alzheimer's disease. The researchers analyzed electronic medical records of thousands of patients, revealing a significant increase in cognitive decline among those receiving ADT.
A new study published in Annals of Oncology shows that abiraterone acetate is effective in treating aggressive prostate cancers, even those with high Gleason scores. The treatment extended progression-free survival by up to 16.5 months in patients previously treated with docetaxel.
A UCLA study found that less than 5% of men with low-risk prostate cancer undergoing active surveillance receive regular monitoring, putting them at risk of cancer progression. The study suggests that patients and doctors should agree on a follow-up schedule to closely monitor the cancer.
A new drug combination is being tested for its effectiveness in treating metastatic prostate cancer. Researchers are optimistic about the results, citing improved quality of life and delayed disease progression in patients participating in a Phase 3 clinical trial.
Two studies found a decline in early-stage prostate cancer incidence and PSA-based screening rates among men 50 years and older following the 2012 USPSTF screening recommendations. The decline was most pronounced in younger men, with significant reductions in PSA screening rates observed between 2010 and 2013.
PSA testing has declined dramatically in middle-aged men after a 2012 recommendation against routine screening, according to a new study. The biggest declines were seen in men ages 50-54 and 60-64 years old.
Researchers found that a secreted bone protein called Sclerostin inhibits prostate cancer metastasis to bone. The study also showed that lack of SOST in the bone microenvironment promotes expression of genes associated with cell migration and invasion.
Men with prostate cancer who undergo radiation therapy can benefit from yoga, which stabilizes fatigue, sexual health, and urinary incontinence. Yoga also improves general quality of life by reducing cancer-related fatigue and strengthening pelvic floor muscles.
A new blood test for prostate cancer significantly improves detection of aggressive cancer, reducing false positives and unnecessary biopsies. The STHLM3 test analyzes protein markers, genetic data, and clinical information to detect cancers in men with low PSA values.
A new study by UCLA researchers reveals a wide range of costs for treating low-risk prostate cancer, with active surveillance being the most cost-effective option. The study used time-driven activity-based costing to analyze costs across an entire care process, finding significant variation in prices for different treatments.
A new clinical trial has shown that a gene-targeted drug, olaparib, can benefit up to 33% of patients with treatment-resistant advanced prostate cancer. The trial found that men whose tumours had defects in DNA repair machinery responded particularly well to the drug.
A new genetic discovery has identified a significant gene called miR137 that is switched off in prostate cancer cells, contributing to the disease's initiation and progression. The study also identified potential targets for next-generation drugs to treat prostate cancer.
Black men with localized prostate cancer had poorer quality care, higher costs, and worse postoperative outcomes compared to white men. However, the authors found no difference in cancer-specific or overall death between the two groups.
The RTOG 9601 study found that adding anti-androgen therapy to salvage radiotherapy improved overall survival and reduced prostate cancer death. The treatment also showed no significant increase in radiation toxicity.
Primary care providers should screen men aged 45 and older with a digital rectal exam (DRE) and prostate-specific antigen (PSA) test. If the patient is asymptomatic, a 5-year screening interval may be considered.